Onconetix, Inc.: second 1:10 reverse stock split effective Nov 6, 2026

What happened The 8-K announced that on Oct 22, 2026 the board determined to effect an additional 1:10 reverse stock split of the company’s common stock, expected to become effective at 12:01 a.m. Eastern Time on Nov 6, 2026. The filing states this reverse stock split, together with a 1:10 reverse stock split previously effected on May 21, 2026, will result in an aggregate reverse stock split ratio of 1:100 under the authorization approved by stockholders at the special meeting on Apr 30, 2026.

Key details

• The company expects to file a Certificate of Amendment to the charter on Nov 5, 2026; trading on a split-adjusted basis is expected to begin when The Nasdaq Stock Market opens on Nov 6, 2026 under the existing symbol “ONCO” and new CUSIP 68237Q500.
• At the Effective Time, every 10 shares of issued and outstanding common stock will be combined into 1 share; no change in authorized shares or par value per share is expected.
• Outstanding shares are expected to be reduced from approximately 5,900,000 shares to approximately 589,000 shares.
• No fractional shares will be issued; holders entitled to fractional shares will receive a cash payment equal to the fraction multiplied by the closing sale price on The Nasdaq Capital Market on the trading day immediately preceding the Effective Time; equity awards, convertible preferred stock and warrants will be proportionally adjusted.

Why it may matter The company reported Item 8.01 (other events), which covers the board’s determination to effect the reverse stock split and related procedural and trading details. This filing does not show why the insider traded or why the company acted.